Cargando…

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis

PURPOSE: To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perraudin, Clémence, Bourdin, Aline, Vicino, Alex, Kuntzer, Thierry, Bugnon, Olivier, Berger, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688145/ https://www.ncbi.nlm.nih.gov/pubmed/33237959 http://dx.doi.org/10.1371/journal.pone.0242630

Ejemplares similares

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Implementation and Effectiveness of an Interprofessional Support Program for Patients with Type 2 Diabetes in Swiss Primary Care: A Study Protocol
por: Bawab, Noura, et al.
Publicado: (2020)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

A Case of Paraneoplastic Demyelinating Motor Polyneuropathy
por: Mostoufizadeh, Sohrab, et al.
Publicado: (2012)

Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study
por: Alonge, Paolo, et al.
Publicado: (2022)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A., et al.
Publicado: (2018)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
por: Belmokhtar, Chafké, et al.
Publicado: (2019)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland — a qualitative study
por: Bourdin, Aline, et al.
Publicado: (2020)

Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
por: Bourdin, Aline, et al.
Publicado: (2021)

Implementation of an interprofessional medication adherence program for chronic patients in community pharmacies: how much does it cost for the provider?
por: Perraudin, Clemence, et al.
Publicado: (2019)

Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient
por: Renard, Delphine, et al.
Publicado: (2012)

Continuity of care and multimorbidity in the 50+ Swiss population: An analysis of claims data
por: Nicolet, Anna, et al.
Publicado: (2022)

Axon reflex-mediated vasodilation is reduced in proportion to disease severity in familial amyloid polyneuropathy
por: Kuntzer, Thierry, et al.
Publicado: (2015)

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
por: Ghosn, Jaqueline, et al.
Publicado: (2018)

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
por: Ritter, Christian, et al.
Publicado: (2015)

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
por: Seino, Yusuke, et al.
Publicado: (2018)

Effectiveness of an Interprofessional Program (Siscare) for Supporting Patients With Type 2 Diabetes
por: Bawab, Noura, et al.
Publicado: (2023)

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
por: Reghukumar, Aravind, et al.
Publicado: (2014)

Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
por: Fatehi, Farzad, et al.
Publicado: (2013)

Chronic Acquired Demyelinating Polyneuropathy following Renal Transplantation
por: Younger, D. S., et al.
Publicado: (2013)

Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy
por: Sung, Woo Kyung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oubg3e15ds1vb4cvt4veal9m68